Alternative Therapy for Patients With Obstructive Sleep Apnea/Hypopnea Syndrome: A 1-year, Single-blind, Randomized Trial of Tui Na

被引:1
|
作者
Lu, Cheng-Nan [1 ,2 ]
Friedman, Michael [3 ,4 ]
Lin, Hsin-Ching [2 ,5 ,6 ]
Bi, Kuo-Wei [2 ,7 ]
Hsueh, Tun-Pin [2 ,8 ]
Chang, Hsueh-Wen [9 ]
Su, Mao-Chang [2 ,10 ]
Lin, Meng-Chih [2 ,10 ]
机构
[1] KCGMH, Dept Tradit Chinese Med TCM, Div Acupuncture & Chinese Traumatol, Kaohsiung, Taiwan
[2] CGUCM, Kaohsiung, Taiwan
[3] Rush Univ, Dept Otolaryngol Head & Neck Surg, Med Ctr, Chicago, IL 60612 USA
[4] Advocate Illinois Masonic Med Ctr, Adv Ctr Specialty Care, Dept Otolaryngol, Chicago, IL USA
[5] KCGMH, Dept Otolaryngol, Kaohsiung, Taiwan
[6] KCGMH, Sleep Ctr, Kaohsiung, Taiwan
[7] KCGMH, Div Acupuncture & Chinese Traumatol, Dept TCM, Kaohsiung, Taiwan
[8] KCGMH, Div Chinese Internal Med, Dept TCM, Kaohsiung, Taiwan
[9] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan
[10] KCGMH, Div Pulm & Crit Care Med, Sleep Ctr, Dept Internal Med, Kaohsiung, Taiwan
关键词
POSITIVE AIRWAY PRESSURE; TONGUE BASE RESECTION; MIDDLE-EAR FUNCTION; QUALITY-OF-LIFE; MASSAGE THERAPY; APNOEA/HYPOPNOEA SYNDROME; APNEA-HYPOPNEA; SURGERY; ADULTS; METAANALYSIS;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Context . Obstructive sleep apnea/hypopnea syndrome (OSAHS) is among the most prevalent of sleep-related breathing disorders. No long-term follow-up studies have documented the continued success of lifestyle changes in treatment; oral appliances have an approximate 50% success rate; compliance with continuous positive airway pressure is poor, ranging from 50% to 89%; and the success rate of upper-airway surgery is only 66.4%. Therefore, some OSAHS patients seek alternative treatments. Objectives . The study intended to examine the efficacy of traditional Chinese therapeutic massage (tui na) for patients with OSAHS. Design . The research team designed a prospective study. Setting . The study took place at the outpatient clinic of the sleep center at the Kaohsiung Chang Gung Memorial Hospital (Kaohsiung, Taiwan), an academic tertiary medical center. Participants . Participants were 31 patients with moderate to severe OSAHS. Intervention . Each participant received a tui na treatment at multiple acupoints 2 x/wk for 10 wk for approximately 15 min/session. Outcome Measures . At baseline and 3 mo after treatment, participants completed subjective measures, including (1) quality of life using a 36-item, short-form health survey (SF-36); (2) subjective snoring intensity indicated by bed-partners using a 0-10 visual analog scale (VAS); and (3) excessive daytime sleepiness (EDS) status, using a Chinese version of the Epworth Sleepiness Scale (CESS). The research team completed objective measures, including (1) polysomnography, (2) body mass index, and (3) neck circumference. Results . Twenty patients completed the full course of treatment. The apnea/hypopnea index per hour decreased from 43.8 +/- 26.9 to 37.8 +/- 31.7 after the treatments, with P = .049 (paired t test). The arousal index and rapid eye movement stage of sleep improved significantly. Statistically significant improvements were observed for the SF-36 on the score for the physical component summary, for its subscale for general health, for the mental component summary, and for 2 of its subscales: vitality and mental health. The VAS and the CESS showed that snoring intensity and EDS decreased significantly, respectively. No major complications occurred. Conclusions . Tui na is a feasible and safe treatment for patients with OSAHS. It can improve the quality of life, sleep architecture, snoring intensity, and EDS in patients with moderate-to-severe OSAHS. In the future, a controlled study should be considered to further investigate the effects of tui na for OSAHS.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 41 条
  • [41] Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial
    Bogers, Jan P. A. M.
    Schulte, Peter F. J.
    Broekman, Theo G.
    Moleman, Peter
    de Haan, Lieuwe
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (09) : 1024 - 1034